Bittner.Dental in Dresden, Saxony

Info
Map & Directions
  • No Records Found

    Sorry, no records were found. Please adjust your search criteria and try again.

    Google Map Not Loaded

    Sorry, unable to load Google Maps API.

  • Bittner.Dental

  • dental-art-dresden GmbH

  • dental-art-dresden GmbH

  • Dr. Christine Lonnstrom

  • Zahn & Art Zahnarzt Dresden – Zahnärztliche Gemeinschaftspraxis Maresch & Henze

  • Zahn & Art Zahnarzt Dresden – Zahnärztliche Gemeinschaftspraxis Maresch & Henze

  • Where to Find Low-Cost Dental Cleanings in Bakersfield, California

    This article helps readers in Bakersfield, California find affordable dental cleanings by outlining where to look for low-cost options, including community health centers, dental schools, nonprofit clinics, and sliding-scale programs. It explains how to compare fees, confirm eligibility for reduced rates, and understand what a low-cost cleaning typically includes. Practical tips—calling ahead, asking about bundled services or payment plans, and exploring local assistance programs—empower families to plan care without financial strain. The piece offers reliable, up-to-date information to support patients and caregivers in maintaining oral health with affordable options.

  • Aurora Bay Area Prices – ATROPINE SULFATE 0.4 MG/ML IJ SOLN(PF AND NON PF)(WRAPPED) is $0.77

    At Aurora Bay Area, we prioritize providing our patients with comprehensive financial information upfront. For Charge Code 10002800, regarding ATROPINE SULFATE 0.4 MG/ML IJ SOLN(PF AND NON PF)(WRAPPED), which is classified under revenue code 250 and associated with CPT code J0461, the designated fee stands at $0.77. Our aim through the CompareMedCosts program is to furnish you with all the details you need to make informed healthcare decisions, offering clarity and transparency around the costs associated with your care.

  • FDA’s GLP-1 compounding proposal could affect obesity care

    The FDA has proposed excluding semaglutide, tirzepatide, and liraglutide from a federal list used by some outsourcing compounders. If finalized, the change could narrow access to some compounded GLP-1 weight-loss products. The proposal does not change the approval status of brand-name obesity medicines. It does raise fresh questions about access, quality, and how compounded versions differ from FDA-approved drugs.